JP2014505012A5 - - Google Patents

Info

Publication number

JP2014505012A5

JP2014505012A5 JP2013535058A JP2013535058A JP2014505012A5 JP 2014505012 A5 JP2014505012 A5 JP 2014505012A5 JP 2013535058 A JP2013535058 A JP 2013535058A JP 2013535058 A JP2013535058 A JP 2013535058A JP 2014505012 A5 JP2014505012 A5 JP 2014505012A5

Authority

JP

Japan

Prior art keywords

monoclonal antibody

amino acid

acid sequence

seq

cell culture

Prior art date

2011-10-19

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims description 94
• 238000004113 cell culture Methods 0.000 claims description 50
• 102000010451 Folate receptor alpha Human genes 0.000 claims description 46
• 108050001931 Folate receptor alpha Proteins 0.000 claims description 46
• 210000004027 cell Anatomy 0.000 claims description 30
• 238000000034 method Methods 0.000 claims description 26
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 17
• 239000004472 Lysine Substances 0.000 claims description 17
• 210000004899 c-terminal region Anatomy 0.000 claims description 17
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 17
• 230000003247 decreasing effect Effects 0.000 claims description 16
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
• 229910052760 oxygen Inorganic materials 0.000 claims description 12
• 239000001301 oxygen Substances 0.000 claims description 12
• 230000007935 neutral effect Effects 0.000 claims description 11
• 150000004676 glycans Chemical class 0.000 claims description 9
• ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 8
• MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 7
• 150000007523 nucleic acids Chemical class 0.000 claims description 7
• 102000039446 nucleic acids Human genes 0.000 claims description 7
• 108020004707 nucleic acids Proteins 0.000 claims description 7
• 101100186981 Arabidopsis thaliana NGA2 gene Proteins 0.000 claims description 6
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 229930182830 galactose Natural products 0.000 claims description 5
• 101150026078 MAN5 gene Proteins 0.000 claims description 4
• 239000012472 biological sample Substances 0.000 claims description 4
• 230000010261 cell growth Effects 0.000 claims description 4
• 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
• 238000012258 culturing Methods 0.000 claims description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
• 239000008103 glucose Substances 0.000 claims 4
• 150000001413 amino acids Chemical class 0.000 claims 1
• 230000003013 cytotoxicity Effects 0.000 claims 1
• 231100000135 cytotoxicity Toxicity 0.000 claims 1
• 230000001419 dependent effect Effects 0.000 claims 1
• 230000013595 glycosylation Effects 0.000 claims 1
• 238000006206 glycosylation reaction Methods 0.000 claims 1
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 9
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 201000001342 Fallopian tube cancer Diseases 0.000 description 1
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1